ClinicalTrials.gg
CompletedNCT05648851MPSIIIDUpdated Aug 1, 2025

A Natural History Study of Sanfilippo Syndrome Type D

An observational study in Sanfilippo Syndrome Type D, sponsored by Phoenix Nest. Completed at 1 site in United States. Open to participants aged 12 Months and older. Per ClinicalTrials.gov, last updated 2025-08-01.

Sponsored by Phoenix Nest · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
10
Ages
12 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Mucopolysaccharidosis III with a site in United States — 12 open to participants now, 15 under way, 4 of them phase 3. Mucopolysaccharidosis III · United States.

Enrollment
17th of 19
10 · median 30
Started
2023
with 2 others
Observational
19 of 43
5 open now
Registered
31st of 43
by date
Lead sponsor
3 of 43
Phoenix Nest

Among the 43 studies in Mucopolysaccharidosis III with a site in United States, this one is the 17th largest by enrollment of the 19 observational ones that give a count, is one of 3 that started in 2023, is one of 19 observational ones, and was the 31st registered.

Mucopolysaccharidosis III

58 studies on the registry are indexed under Mucopolysaccharidosis III; 16 are open to participants now.

Browse Mucopolysaccharidosis III studies →

Open to participants now

12 of the 43 studies in Mucopolysaccharidosis III with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Mucopolysaccharidosis III studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 12 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Mucopolysaccharidosis III with a site in United States, or all of them as a file.
02

Study summary

Sanfilippo syndrome type D is a ultra rare syndrome with limited available natural history data. This study is planned to document, through retrospective and prospective data collection, syndrome progression in children and young adults with Sanfilippo syndrome type D. The results from this study may inform future clinical studies in targeted therapies for patients with Sanfilippo syndrome type D and may serve as an external control since there are very few patients with Sanfilippo syndrome type D.

Read the detailed description

This is a single-center, natural history study of subjects with Sanfilippo syndrome type D. This study will combine a retrospective review of medical records and an ongoing collection of clinical data on an observational basis from participants with Sanfilippo syndrome type D.

Participants will be asked to attend clinic visits in person on a yearly basis. In clinic visits will include neurocognitive, developmental, behavioral, biochemical, imaging measures as well as retrospective medical record analysis. At 6-month intervals between clinic visits, participants will be contacted remotely for some safety assessments (e.g., collecting information about concomitant medications, concurrent illnesses, and procedure-related adverse events [AEs] and serious AEs [SAEs] since last clinic visit). At 6-month intervals, caregivers will complete questionnaires and record home video assessments using a dedicated, compliant study application (app) called RARE (Recording Application for Real-World Evidence). The RARE app consists of 9 tasks of Activities of Daily Living and socialization as well as two parent reported questionnaires.

No formal power or sample size calculations will be performed. At least 4 and up to 10 patients living with Sanfilippo syndrome type D will be enrolled in the prospective and retrospective study (group/cohort 1). An additional 5 patients deceased or living will be enrolled for retrospective medical record collection only (group/cohort 2).

The objectives of this study are:

  1. To enhance the understanding of the natural history and progression of Sanfilippo syndrome type D.
  2. To define and categorize clinical endpoints that may be used in future clinical trials.
03

Conditions studied

  • Sanfilippo Syndrome Type D

Keywords

  • Sanfilippo syndrome type D
  • mucopolysaccharidosis
  • MPSIIID
04

Who can participate

Ages eligible
12 Months and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a documented diagnosis of Sanfilippo syndrome type D and who are currently untreated with investigational products (drugs/device) for this disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in the study, patients must meet all of the following criteria:

  1. Confirmed diagnosis of Sanfilippo syndrome type D disease by all of the following:

    1. Deficiency in alpha-GNS enzyme activity
    2. Has presented with signs/symptoms consistent with Sanfilippo syndrome type D, or, for individuals who have not presented with signs/symptoms of disease (eg, siblings of known patients), the determination of eligibility will be at the discretion of the Sponsor in conjunction with the site Investigator
    3. Genomic DNA analysis demonstrating homozygous or compound heterozygous, pathogenic and/or potentially pathogenic variants in the GNS gene
    4. Accumulated GAG HS in urine
  2. Written from parent or legal guardian and assent from patient, if required
  3. Parent/legal guardian willing to accompany the patient to all study visits
  4. Ability to comply with protocol requirements, in the opinion of the Investigator
  5. Negative urine pregnancy test at screening (nonsterile females of only) -

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will not be eligible to participate in the study:

  1. Have received an drug within 30 days prior to the Baseline Visit
  2. Concomitant illness or medical condition or extenuating circumstance that, in the opinion of the Investigator, might compromise the patient's ability to comply with protocol requirements, the patient's well-being or safety, or the interpretability of the patient's clinical data
  3. The presence of significant non-MPS IIID-related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study -
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
10 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group 1 In person combination retrospective and prospective Natural History Study

    Combination retrospective and prospective Natural History Study of patients living with Sanfilippo syndrome type D. The study will include home video of daily living activities via the RARE app, a mobile app designed for this study. In clinic visits will include neurocognitive, developmental, behavioral, biochemical, imaging measures as well as retrospective medical record analysis.

  • Group 2 Retrospective medical record analysis

    Retrospective collection and analysis of medical records of deceased or living patients.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Cognitive function

    Assessed using the Leiter-3, evaluation of nonverbal cognitive, neuropsychological abilities. The Leiter-3 emphasizes fluid intelligence a measure of the individuals innate cognitive abilities. Children's Color Trail Test (CCTT) assesses sustained attention, sequencing, and other executive functions while reducing reliance on language.

    Time frame: Baseline, 12 months and 24 months

  2. Change From Baseline in Motor function

    Assessed using the MFM-32, 25 foot walk test in the clinic at baseline, 12 months and 24 months and video tasks via the RARE app task assessments: 'walking up/down stairs', 'transferring to sit' at baseline, 6 months, 12 months, 18 months and 24 months. Fine and gross motor skills will be assess at baseline, 6 months, 12 months, 18 months and 24 months via the RARE app task assessments: 'writing on paper', 'eating snack', 'looking at book', 'playing Uno', 'washing hands' and 'putting on jacket'.

    Time frame: up to 24 months

  3. Change From Baseline in Speech and language abilities

    Assessed using the Preschool Language Scales Fifth Edition (PLS-5); parent reported questionnaire to be administered in the clinic at baseline, 12 months, 24 months. The PLS-5 is a comprehensive developmental language tool with questions that range from pre-verbal, interaction-based skills to emerging language to early literacy. Picture description is an informal speech tool used to analyze structural language skills, patients speech will be captured via the RARE app in the clinic at baseline, 12 months and 24 months. Expressive and receptive language abilities are embedded in several of the RARE app tasks: 'looking at book', 'playing Uno', 'putting on jacket' and will be captured at baseline, 6 months, 12 months, 18 months and 24 months.

    Time frame: up to 24 months

Secondary outcomes

  1. Change From Baseline in Functional abilities

    Participants functional abilities will be captured via the RARE app at baseline, 6 months, 12 months, 18 months, 24 months while performing tasks of Activities of Daily Living (ADLs). ADLs include: Clothing Management, Eating and Drinking, Chewing and Swallowing, Hygiene, Maintaining and Changing positions, Writing Skills, and Walking. The Vineland Adaptive Behavioral Scales second addition (VABS-II) ia a parent reported clinical outcome assessment which will be administered in the clinic at baseline, 12 months and 24 months. The VABS-II Domains: Communication, Daily Living Skills, Socialization and Motor Skills will be used to assess patient's functional abilities.

    Time frame: up to 24 months

07

Study locations

1 site
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
08

References and documents

Individual participant data

Plan to share: Undecided — The data collected as part of the observational study may be analyzed and published. Phoenix Nest recognizes the importance of communicating medical study data and therefore encourages the publication of these data in reputable scientific journals and at seminars or conferences. The details of the processes of producing and reviewing reports, manuscripts, and presentations based on the data from this study will be described in the Clinical Trial Agreement between Phoenix Nest and the Investigator/institution. Consideration for authorship of all publications will be based on compliance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals ("Uniform Requirements") of the International Committee of Medical Journal Editors (http://www.icmje.org/ethical_1author.html) and Good Publication Practices.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Nov 2024, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2022
First posted
Dec 13, 2022
StartActual
Jan 22, 2023
Primary completionActual
Nov 1, 2024
CompletionActual
Nov 1, 2024
Last update
Aug 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05648851
Lead sponsor
Phoenix Nest
Responsible party
Sponsor
First posted
Dec 13, 2022
Start date
Jan 22, 2023
Primary completion
Nov 1, 2024
Completion
Nov 1, 2024
Last update
Aug 1, 2025

Study contacts

Wendy Chung, MD
principal investigator · Columbia University Department of Pediatrics
Andres Morales, MD
principal investigator · Columbia University Department of Pediatrics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion